Morphic Holding Inc

Morphic — Technical Presentation (April 2023)

16 slides from Morphic's technical presentation, Apr 25, 2023

  1. Slide 1: EMERALD-1 Topline Data

    EMERALD - 1 Topline Data April 25, 2023

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing cl inical t

  3. Slide 3: Agenda and Participants

    Agenda and Participants 3 Introductory Remarks: Praveen Tipirneni UC Treatment Landscape: Dr. Bruce Sands EMERALD - 1 Overview & Safety: Brihad Abhyankar Clinical Data: Bruce Rogers Closing Remarks: Praveen Tipirneni Q&A Present for Q&A: Management and Key Opinion Leader Bruce Sands, MD Dr. Burrill

  4. Slide 4: The Unmet Need in IBD Treatment

    The Unmet Need in IBD Treatment 4 Safe and Well Tolerated Convenient O ral Administration Compelling Clinical Efficacy

  5. Slide 5: EMERALD-1 Trial Overview

    EMERALD - 1 Trial Overview Phase 2a open - label single - arm study of MORF - 057 (100mg BID) in patients with moderately to severely active ulcerative colitis (UC) – N=35 in main cohort 5 • Primary endpoint: Change in RHI measured at 12 weeks • Secondary endpoint : mMCS change from baseline, safety

  6. Slide 6: Baseline Patient Demographics

    Baseline Patient Demographics N=35 Age, years, mean (SD) 39.2 (14.1) Sex, n (%), female/male 16 (45.7%) / 19 (54.3%) Geography, n (%), Poland/US 28 (80%) / 7 (20%) Baseline RHI, mean (SD) 22.7 (7.3) mMCS , mean (SD) 6.7 (1.1) Mayo Endoscopy Score (MES), n (%), 2/ 3 18 (51.4%) / 17 ( 48.6% ) Advanced

  7. Slide 7: MORF-057: Generally Well-Tolerated in EMERALD-1, No Safety Signal Observed

    MORF - 057: Generally Well - Tolerated in EMERALD - 1 No Safety Signal Observed Adverse Event (AE) profile consistent with underlying disease state 7 Patients with at least one AE 12 (34.3%) Patients with any serious AE 0 Patients with AE leading to death 0 Patients with any grade 3 AE 2 (5.7%) 1 Pa

  8. Slide 8: Topline Clinical Data

    Topline Clinical Data

  9. Slide 9: Patient PK Consistent with Healthy Volunteer PK

    Patient PK Consistent with Healthy Volunteer PK 9 0 2 4 6 10 100 1000 Nominal Time (hr) C o n c e n t r a t i o n ( n g / m L ) Ph-1, Day 14 Ph-1, Day 1 Ph-2 EMERALD 1, Day 1 Ph-2 EMERALD 1, Day 15 Ph-2 EMERALD 1, Day 85 • Serum drug concentrations conform highly to Phase 1 healthy volunteer data •

  10. Slide 10: Patient α4β7 Receptor Occupancy Consistent with Healthy Volunteer RO

    Patient a4β7 Receptor Occupancy (RO) Consistent with Healthy Volunteer RO 10 a4β7 selectivity over a4β1 consistent with Phase 1 results RO at 12 weeks a4β7 a4β1 Mean >98% BLQ Median >99% BLQ • a4β7 RO achieved early and sustained saturating levels • a4β1 RO remained at low levels • No lymphocytosis

  11. Slide 11: Consistent Clinical Improvement Across Key Measures

    Consistent Clinical Improvement Across Key Measures 11 Change in RHI from Baseline Primary Endpoint - 6.4 (p=.0019) mMCS Mean Change from Baseline Secondary Endpoint - 2.3 mMCS Remission mMCS: Rectal bleeding sub - score of 0; a stool frequency sub - score of ≤1; and an MES of ≤1 without friability

  12. Slide 12: Strong RHI Results Support MORF-057

    - 6.4 -9 -7 -5 -3 -1 MORF-057 0 - 7.5 - 5.0 ENTYVIO HUMIRA N=35 N=383 N=386 Strong RHI Results Support MORF - 057 12 • Baseline RHI: • 22.7 (7.32) • 12 - week timepoint • 37% advanced therapy experienced patients • Open - label, single a rm • Baseline RHI: • ENTYVIO ® - 19.5 (8.7) • HUMIRA ® – 19.6

  13. Slide 13: UC Absolute Clinical Remission Data at Induction

    UC Absolute Clinical Remission Data at Induction Selected Approved and Investigational Agents 13 • PRA - 023 and MORF - 057 data from Phase 2 trials; all other data from RCT Phase 3 studies. G raphic is not meant to represent a head - to - head study. Comparing the results from different trials may

  14. Slide 14: The Unmet Need in IBD Treatment

    The Unmet Need in IBD Treatment 14 Safe and Well Tolerated Convenient O ral Administration Compelling Clinical Efficacy

  15. Slide 15: Q&A

    Q&A 15 Key Opinion Leader Bruce Sands, MD Dr. Burrill B. Crohn Professor of Medicine and Chief of Gastroenterology at Mount Sinai Hospital Praveen Tipirneni, MD Chief Executive Officer Bruce Rogers, PhD President Marc Schegerin, MD Chief Operating Officer & Chief Financial Officer Brihad Abhyankar,

  16. Slide 16: Thank You

    Thank You

Morphic Holding — Technical Presentation (April 2023) on 6ix